Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11543788 | 0.80 | LMNA (0.41) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL11698200 | 0.78 | KMT2A (0.41) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL4354498 | 0.77 | ALDH1A1 (0.41) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL15277537 | 0.77 | PKM (0.40) | PKMMAPTGAA | |
| SCHEMBL16654250 | 0.77 | DYRK1A (0.37) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12636691 | 0.76 | MAPT (0.38) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL7352542 | 0.75 | TSHR (0.56) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL23284547 | 0.74 | PIK3CG (0.37) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL16402575 | 0.74 | KMT2A (0.37) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL4354444 | 0.74 | PIK3CG (0.37) | TSHRLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561836-A1 | SUBSTITUTED 5-AMINOPYRAZOLS | BASF Aktiengesellschaft (DE) | 1993-09-29 | — | — | EP | claimed |
| WO-1992010480-A1 | SUBSTITUTED 5-AMINOPYRAZOLS | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-25 | — | — | WO | claimed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117924277-A | Oxime ether compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| CN-101421268-B | As the pyrazolo quinolone of effective PARP inhibitor | ABBVIE (US) | 2016-01-06 | — | — | CN | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20050153059-A1 | Partial plating method, partially-plated resin base, method for manufacturing multilayered circuit board | ZEON CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004106492-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040237295-A1 | Multilayer circuit board and resin base material, and its production method | ZEON CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
| WO-2004087056-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ | SCIOS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-5541187-A | HYPOTENSIVE AGENTS | STERLING WINTHROP INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0636626-A1 | Pyrazolopyrimidine Derivatives | LABORATOIRES GLAXO SA (FR) | 1995-02-01 | — | — | EP | disclosed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | TSHR 4731/4885LMNA 678/4885ALDH1A1 1375/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | TSHR 3220/4885LMNA 2007/4885ALDH1A1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.